Biocytogen Pharmaceuticals-B (02315) Announcement of Expected Performance Increase for the First Half of 2026: Revenue Maintains Rapid Growth, Scalable Profitability Accelerates Release

On August 6, Biocytogen Pharmaceuticals-B (02315, 688796.SH) released its performance forecast for the first half of 2026. According to preliminary calculations by the company's finance department, it is expected that the operating revenue for the first half of 2026 will reach between 936 million and 946 million yuan (RMB, the same below), which represents an increase of 315 million to 325 million yuan compared to the same period last year, with a year-on-year growth of 50.80% to 52.41%. The net profit attributable to the owners of the parent company is expected to be between 236 million and 246 million yuan, an increase of 188 million to 198 million yuan compared to the same period last year, reflecting a year-on-year growth of 391.87% to 412.71%. The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses is expected to be between 192 million and 202 million yuan, an increase of 164 million to 174 million yuan compared to the same period last year, with a year-on-year growth of 574.02% to 609.04%. As the biopharmaceutical industry enters a new stage of innovation-driven development, the company leverages its forward-looking research and development layout, leading products, and high-quality services, as well as a premium customer network covering top global pharmaceutical companies and leading biotechnology firms, to fully unleash its competitive advantages and seize the business development opportunities brought about by the improved industry dynamics. During the reporting period, both of the company's two major business lines achieved dual-wheel drive and leapfrog collaboration, driving the continuous high-speed growth of operating revenue. With the significant enhancement of the company's revenue scale and industry position, the scale effects of its production capacity and operations are accelerating. Based on this, along with the continuous deepening of lean management, the company effectively achieves cost reduction and efficiency improvement, which drives the overall gross profit margin to further increase while the period expense ratio effectively decreases, significantly enhancing the company's profitability and accelerating the release of scaled profits. Biocytogen Pharmaceuticals is an international biotechnology company driven by innovative technology for new drug research and development, dedicated to becoming a global source of new drugs. The company focuses on its self-developed gene editing technology to build a dual-engine platform of "fully human antibody molecular library + targeted humanized mouse library" to systematically accelerate global drug research and development. Biocytogen Pharmaceuticals has independently developed the RenMice fully human antibody platform (which includes RenMab, RenLite, RenNano, RenTCR, and RenTCR mimic) for the discovery of therapeutic fully human monoclonal antibodies, bispecific/multispecific antibodies, dual antibody ADCs, nanobodies, and TCR-like antibodies. With over 1,000 potential druggable targets, the company is advancing a large-scale antibody discovery program "Thousand Mice, Ten Thousand Antibodies" and has established a library of over 1 million authentic fully human antibody sequences, opening up for global cooperation. As of December 31, 2025, Biocytogen Pharmaceuticals has signed over 350 drug collaboration development/authorization/transfer agreements. The company's sub-brand Bai'ao Animals has established thousands of gene-editing animal/cell models and possesses the world's leading scale of targeted humanized mouse libraries, providing global clients with comprehensive capabilities in preclinical pharmacology and efficacy studies, gene editing services, model construction, and more. Biocytogen Pharmaceuticals is headquartered in Beijing and has branches in China (Haimen, Jiangsu and Shanghai), the United States (Boston, San Francisco, San Diego), and Heidelberg, Germany, forming a global research and development and operational network.